文献速递淋巴瘤

识别高活性抗CCR4 CAR T细胞用于治疗T细胞淋巴瘤

Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma.
PubMed 文献 · Blood Adv · 2023-01-01

靶向T细胞淋巴瘤的CAR T细胞因抗原在T细胞与肿瘤细胞共享而存在自相残杀问题。CCR4在ATLL和CTCL等成熟T细胞恶性肿瘤高表达,在正常T细胞中主要表达于Th2、Th17和Treg。本研究显示抗CCR4 CAR T细胞特异性清除Th2和Treg而保留CD8+和Th1,自相残杀提高终产物CAR+比例,并在小鼠中诱导优于对照的抗肿瘤疗效和长期缓解。

要点

  • 抗CCR4 CAR T细胞在转导和扩增中快速自相残杀清除CCR4阳性T细胞。
  • 自相残杀特异性清除Th2和Treg,保留CD8+和Th1 T细胞。
  • 基于mogamulizumab的CCR4-CAR T细胞在小鼠中诱导更优抗肿瘤疗效和长期缓解。

核心结论

  • CCR4清除的抗CCR4 CAR T细胞富集Th1和CD8+ T细胞,对CCR4表达的T细胞恶性肿瘤显示高抗肿瘤疗效。

研究设计与样本

  • 研究为体外和体内实验,使用mogamulizumab为基础构建的抗CCR4 CAR T细胞,并在植入人T细胞淋巴瘤细胞的小鼠中评估疗效。

主要发现

  • 抗CCR4 CAR T细胞在CAR转导和扩增过程中快速自相残杀清除CCR4阳性T细胞。
  • 自相残杀特异性清除Th2和Treg,同时保留CD8+和Th1 T细胞。
  • 自相残杀增加终产物中CAR+ T细胞的百分比。
  • CCR4-CAR T细胞具有高转导效率和强劲的T细胞扩增。
  • 基于mogamulizumab的CCR4-CAR T细胞在植入人T细胞淋巴瘤细胞的小鼠中诱导更优的抗肿瘤疗效和长期缓解。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A challenge when targeting T-cell lymphoma with chimeric antigen receptor (CAR) T-cell therapy is that target antigens are often shared between T cells and tumor cells, resulting in fratricide between CAR T cells and on-target cytotoxicity on normal T cells. CC chemokine receptor 4 (CCR4) is highly expressed in many mature T-cell malignancies, such as adult T-cell leukemia/lymphoma (ATLL) and cutaneous T-cell lymphoma (CTCL), and has a unique expression profile in normal T cells. CCR4 is predominantly expressed by type-2 and type-17 helper T cells (Th2 and Th17) and regulatory T cells (Treg), but it is rarely expressed by other T helper (Th) subsets and CD8+ cells. Although fratricide in CAR T cells is generally thought to be detrimental to anticancer functions, in this study, we demonstrated that anti-CCR4 CAR T cells specifically depleted Th2 and Tregs, while sparing CD8+ and Th1 T cells. Moreover, fratricide increased the percentage of CAR+ T cells in the final product. CCR4-CAR T cells were characterized by high transduction efficiency, robust T-cell expansion, and rapid fratricidal depletion of CCR4-positive T cells during CAR transduction and expansion. Furthermore, mogamulizumab-based CCR4-CAR T cells induced superior antitumor efficacy and long-term remission in mice engrafted with human T-cell lymphoma cells. In summary, CCR4-depleted anti-CCR4 CAR T cells are enriched in Th1 and CD8+ T cells and exhibit high antitumor efficacy against CCR4-expressing T-cell malignancies.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Watanabe K, Gomez AM, Kuramitsu S, et al. Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma. Blood Adv. 2023. PMID: 37058474. doi:10.1182/bloodadvances.2022008327

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。